Results 211 to 220 of about 843,559 (297)

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang   +16 more
wiley   +1 more source

NeoThy™ immune-humanized mice can produce anti-drug antibodies to support immunogenicity assessment for biological drug products. [PDF]

open access: yesFront Immunol
Gharaie S   +10 more
europepmc   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

open access: yesCancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato   +5 more
wiley   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2336-2346, November 2026.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

A Humanized Anti-gD Broadly Neutralizing Antibody Confers Complete Post-Exposure Protection Against Pseudorabies Virus. [PDF]

open access: yesAdv Sci (Weinh)
Sun Y   +11 more
europepmc   +1 more source

Identification of C3d Complement Fragments in Lesional Tissues in ANCA‐Associated Vasculitis

open access: yesACR Open Rheumatology, Volume 8, Issue 11, November 2026.
Objective Antineutrophil cytoplasmic antibody–associated vasculitis (AAV) is typically described as “pauci‐immune” due to the absence or weak detection of Igs and complement activation within AAV tissue lesions. However, complement fragments have been recently reported in significant amounts in damaged tissue in AAV, notably in traps formed by ...
Claire Galand   +19 more
wiley   +1 more source

Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT. [PDF]

open access: yesBlood Adv
Tawhidi Z   +11 more
europepmc   +1 more source

Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Raj Chovatiya   +9 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy